Theralase Technologies (TTX) AI Stock Analysis

1 Followers

Theralase Technologies

(Frankfurt:TTX)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageThe very low debt burden reduces refinancing pressure and preserves financial flexibility relative to a more leveraged medical technology company. This gives Theralase greater capacity to direct future capital toward laser commercialization and PDT development rather than servicing substantial fixed obligations.

Negative Factors

Contracting RevenueA small and declining revenue base limits operating scale and suggests that current commercialization has not yet produced durable growth. Continued contraction makes it harder to absorb fixed costs, fund product development internally, and establish a stronger base for sustainable earnings.

Theralase Technologies (TTX) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 57.44M
Dividend Yield: ―
Average Volume (3M): 142.04K
Price to Earnings (P/E): -13.0
Beta (1Y): 0.28
Revenue Growth: -29.59%
EPS Growth: 22.61%
Country: Germany
Employees: 16
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Theralase Technologies Business Overview & Revenue Model

Company Description

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruse...

Theralase Technologies Earnings Call Summary

Earnings Call Date:May 29, 2025(Q1-2025)|% Change Since:-0.93%|Next Earnings Date:May 29, 2020

Earnings Call SentimentNeutral

The earnings call reflects a company at a pivotal moment, with significant progress in clinical studies and plans for expansion into multiple high-value indications. While the financials show a decline in revenue and increased expenses, the strategic initiatives and successful capital raising efforts position Theralase for future growth.

Positive Updates

Completion of Bladder Cancer Study Enrollment

Theralase is on track to complete enrollment in a critical bladder cancer study by the summer of 2025, marking a significant milestone in their clinical development.

Negative Updates

Revenue Decline

Revenue for the first quarter of 2025 was $91,000, down from $175,000 the previous year, reflecting the focus on bladder cancer clinical study completion.

Company Guidance

During the call, Theralase Technologies provided guidance on several metrics and strategic initiatives. The company is on track to complete enrollment in its registrational bladder cancer study by summer 2025, with a 15-month patient follow-up expected to conclude by the third quarter of 2026. Theralase plans to file a New Drug Application with Health Canada and the FDA in the fourth quarter of 2026, aiming for marketing approval in early 2027. Financially, the company reported nominal revenues of $91,000 for Q1 2025, largely from its Cool Laser Therapy systems, down from $175,000 the previous year. Despite a net loss of $1.47 million, Theralase has raised nearly $7.5 million over the past 24 months through private placements. The company is exploring a potential U.S. uplist and institutional financing, which could enhance its capital position and broaden its investor base. Additionally, Theralase is advancing a pipeline that includes nine new indications, with plans for Phase I/II clinical studies in 2026. The company highlighted a 62% complete response rate in its bladder cancer study, emphasizing the safety and efficacy of its Ruvidar treatment.

Theralase Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:TTX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:PRN	58Neutral	CAD 398.50M	-8.53	-59.18%	―	64.70%	30.61%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:ASG	45Neutral	CAD 7.03M	-4.56	-34.32%	―	-5.42%	-5.37%
TSE:PINK	44Neutral	CAD 23.78M	-1.11	-303.05%	―	35.27%	58.34%
TSE:VPT	37Underperform	CAD 12.54M	-5.74	56.40%	―	89.06%	37.62%

* General Sector Average

Performance Comparison

DE:TTX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:TTX	Theralase Technologies	0.11	-0.00	-3.60%
TSE:ASG	Aurora Spine	0.10	-0.20	-66.67%
TSE:PINK	Perimeter Medical Imaging Ai Inc	0.14	-0.04	-19.44%
TSE:PRN	Profound Medical	11.18	2.14	23.67%
TSE:VPT	VentriPoint Diagnostics	0.07	-0.02	-21.05%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Theralase Technologies AI Stock Analysis